肿瘤指南

订阅

MedSci主页 / 所有栏目 / 肿瘤指南

安罗替尼超说明书用药专家共识

2021-12-28 安罗替尼超说明书用药编写专家组 中国现代应用药学

超说明书用药安罗替尼

超说明书用药又称“药品说明书外用法”“药品未注册用法”,是指药品使用的适应证、剂量、疗程、途径或人群等未在药品监督管理部门批准的药品说明书记载范围内的用法。

中文标题：

安罗替尼超说明书用药专家共识

发布机构：

安罗替尼超说明书用药编写专家组

发布日期：

2021-12-28

简要介绍：

超说明书用药又称“药品说明书外用法”“药品未注册用法”,是指药品使用的适应证、剂量、疗程、途径或人群等未在药品监督管理部门批准的药品说明书记载范围内的用法。由于说明书的修改审批程序复杂耗时,因此说明书的更新往往存在滞后性。晚期肿瘤患者一二线标准治疗进展后往往存在治疗方案匮乏的情况,加之肿瘤治疗药物的研究进展较快,因此超说明书用药是临床常见的情况。 

相关资料下载：
[AttachmentFileName(sort=1, fileName=安罗替尼超说明书用药专家共识.pdf)] GetToolGuiderByIdResponse(projectId=1, id=b354a1c00231a570, title=安罗替尼超说明书用药专家共识, enTitle=, guiderFrom=中国现代应用药学, authorId=0, author=, summary=超说明书用药又称“药品说明书外用法”“药品未注册用法”,是指药品使用的适应证、剂量、疗程、途径或人群等未在药品监督管理部门批准的药品说明书记载范围内的用法。, cover=https://img.medsci.cn/202218/1641641774881_5579292.jpg, journalId=0, articlesId=null, associationId=2281, associationName=安罗替尼超说明书用药编写专家组, associationIntro=安罗替尼超说明书用药编写专家组, copyright=0, guiderPublishedTime=Tue Dec 28 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p><span style="color: #333333;">超说明书用药又称&ldquo;药品说明书外用法&rdquo;&ldquo;药品未注册用法&rdquo;,是指药品使用的适应证、剂量、疗程、途径或人群等未在药品监督管理部门批准的药品说明书记载范围内的用法。由于说明书的修改审批程序复杂耗时,因此说明书的更新往往存在滞后性。晚期肿瘤患者一二线标准治疗进展后往往存在治疗方案匮乏的情况,加之肿瘤治疗药物的研究进展较快,因此超说明书用药是临床常见的情况。&nbsp;</span></p>, tagList=[TagDto(tagId=27238, tagName=超说明书用药), TagDto(tagId=28806, tagName=安罗替尼)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=28806, guiderKeyword=安罗替尼, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=4451, appHits=78, showAppHits=0, pcHits=490, showPcHits=4373, likes=0, shares=15, comments=5, approvalStatus=1, publishedTime=Sat Jan 08 19:34:03 CST 2022, publishedTimeString=2021-12-28, pcVisible=1, appVisible=1, editorId=5579292, editor=FUNNYMAN, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=FUNNYMAN, createdTime=Sat Jan 08 19:37:16 CST 2022, updatedBy=5579292, updatedName=FUNNYMAN, updatedTime=Sat Jan 06 18:09:03 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=安罗替尼超说明书用药专家共识.pdf)])
安罗替尼超说明书用药专家共识.pdf
下载请点击：
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1218141, encodeId=e62b1218141d7, content=<a href='/topic/show?id=a20e45830e0' target=_blank style='color:#2F92EE;'>#安罗替尼#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45830, encryptionId=a20e45830e0, topicName=安罗替尼)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Mon May 09 12:58:29 CST 2022, time=2022-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184058, encodeId=90f3118405841, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bd891361130, createdName=chenfang193, createdTime=Thu Jan 13 22:34:43 CST 2022, time=2022-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1183085, encodeId=188a1183085e9, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43086458973, createdName=ms1000001636399617, createdTime=Tue Jan 11 08:43:58 CST 2022, time=2022-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182760, encodeId=8c591182e60de, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33632003406, createdName=新心相映, createdTime=Mon Jan 10 10:03:23 CST 2022, time=2022-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182419, encodeId=c211118241931, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Sun Jan 09 07:23:16 CST 2022, time=2022-01-09, status=1, ipAttribution=)]
    2022-05-09 病毒猎手

    #安罗替尼#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1218141, encodeId=e62b1218141d7, content=<a href='/topic/show?id=a20e45830e0' target=_blank style='color:#2F92EE;'>#安罗替尼#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45830, encryptionId=a20e45830e0, topicName=安罗替尼)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Mon May 09 12:58:29 CST 2022, time=2022-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184058, encodeId=90f3118405841, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bd891361130, createdName=chenfang193, createdTime=Thu Jan 13 22:34:43 CST 2022, time=2022-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1183085, encodeId=188a1183085e9, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43086458973, createdName=ms1000001636399617, createdTime=Tue Jan 11 08:43:58 CST 2022, time=2022-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182760, encodeId=8c591182e60de, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33632003406, createdName=新心相映, createdTime=Mon Jan 10 10:03:23 CST 2022, time=2022-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182419, encodeId=c211118241931, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Sun Jan 09 07:23:16 CST 2022, time=2022-01-09, status=1, ipAttribution=)]
    2022-01-13 chenfang193

    学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1218141, encodeId=e62b1218141d7, content=<a href='/topic/show?id=a20e45830e0' target=_blank style='color:#2F92EE;'>#安罗替尼#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45830, encryptionId=a20e45830e0, topicName=安罗替尼)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Mon May 09 12:58:29 CST 2022, time=2022-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184058, encodeId=90f3118405841, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bd891361130, createdName=chenfang193, createdTime=Thu Jan 13 22:34:43 CST 2022, time=2022-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1183085, encodeId=188a1183085e9, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43086458973, createdName=ms1000001636399617, createdTime=Tue Jan 11 08:43:58 CST 2022, time=2022-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182760, encodeId=8c591182e60de, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33632003406, createdName=新心相映, createdTime=Mon Jan 10 10:03:23 CST 2022, time=2022-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182419, encodeId=c211118241931, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Sun Jan 09 07:23:16 CST 2022, time=2022-01-09, status=1, ipAttribution=)]
    2022-01-11 ms1000001636399617

    学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1218141, encodeId=e62b1218141d7, content=<a href='/topic/show?id=a20e45830e0' target=_blank style='color:#2F92EE;'>#安罗替尼#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45830, encryptionId=a20e45830e0, topicName=安罗替尼)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Mon May 09 12:58:29 CST 2022, time=2022-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184058, encodeId=90f3118405841, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bd891361130, createdName=chenfang193, createdTime=Thu Jan 13 22:34:43 CST 2022, time=2022-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1183085, encodeId=188a1183085e9, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43086458973, createdName=ms1000001636399617, createdTime=Tue Jan 11 08:43:58 CST 2022, time=2022-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182760, encodeId=8c591182e60de, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33632003406, createdName=新心相映, createdTime=Mon Jan 10 10:03:23 CST 2022, time=2022-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182419, encodeId=c211118241931, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Sun Jan 09 07:23:16 CST 2022, time=2022-01-09, status=1, ipAttribution=)]
    2022-01-10 新心相映

    学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1218141, encodeId=e62b1218141d7, content=<a href='/topic/show?id=a20e45830e0' target=_blank style='color:#2F92EE;'>#安罗替尼#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45830, encryptionId=a20e45830e0, topicName=安罗替尼)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Mon May 09 12:58:29 CST 2022, time=2022-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184058, encodeId=90f3118405841, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bd891361130, createdName=chenfang193, createdTime=Thu Jan 13 22:34:43 CST 2022, time=2022-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1183085, encodeId=188a1183085e9, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43086458973, createdName=ms1000001636399617, createdTime=Tue Jan 11 08:43:58 CST 2022, time=2022-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182760, encodeId=8c591182e60de, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33632003406, createdName=新心相映, createdTime=Mon Jan 10 10:03:23 CST 2022, time=2022-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182419, encodeId=c211118241931, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Sun Jan 09 07:23:16 CST 2022, time=2022-01-09, status=1, ipAttribution=)]
    2022-01-09 微探

    学习学习

    0

相关指南

临床重症与药学超说明书用药专家共识（2021新增版）

广东省药学会 · 2021-09-27

山东省超药品说明书用药专家共识（2021 年版

暂未更新 · 2021-06-28

中国儿科超说明书用药专家共识

中华医学会儿科学分会 · 2016-02-29

《超药品说明书用药目录（2016年版）》

广东省药学会 · 2016-05-03

拓展阅读

盐酸安罗替尼治疗晚期肺癌中国专家共识（2020版）

中国医师协会肿瘤医师分会 · 2020-10-30